Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.39
+0.06 (1.13%)
At close: Jan 21, 2025, 4:00 PM
5.41
+0.02 (0.37%)
After-hours: Jan 21, 2025, 7:22 PM EST
Verastem Revenue
Verastem had revenue of $10.00M in the twelve months ending September 30, 2024.
Revenue (ttm)
$10.00M
Revenue Growth
n/a
P/S Ratio
16.29
Revenue / Employee
$136,986
Employees
73
Market Cap
247.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
VSTM News
- 6 days ago - Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - Business Wire
- 7 days ago - Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
- 8 days ago - Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - Business Wire
- 13 days ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Verastem: Planning The PDUFA Run-Up - Seeking Alpha
- 19 days ago - Verastem: BLA Acceptance Puts Key Goals In Sight - Seeking Alpha
- 21 days ago - Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday? - Benzinga
- 22 days ago - Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - Business Wire